PD-L1 (E1L3N) – 149Sm
Catalog: 714901 Clone: E1L3N Isotype: Rabbit IgG
Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store a 4°C
IHC: PD-L1 staining of FFPE human placenta
MIBI: PD-L1 staining (cyan) of FFPE human placenta, counterstained with dsDNA (magenta)
IHC: PD-L1 staining of FFPE human tonsil
MIBI: PD-L1 staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)
Background: Programmed cell death 1 ligand 1 (PD-L1, CD274) binds to PD-1 and inhibits T cell activation. APCs, activated T cells, and tissues including placenta, heart, and lung can express PD-L1. PD-L1 is expressed in cancer as a means for cancerous cells to inhibit immune responses. PD-L1 has been detected for several tumor types including melanoma, lung, ovary, colon, breast, and renal cell carcinomas. PD-L1 expression in cancer is associated with tumor infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma. Inhibition of the PD-1－PD-L1 axis has been an active area of clinical research with several approved drugs for multiple indications.
Validation: Each lot of conjugated antibody is quality control tested by MIBIscope™ analysis of stained tissue microarray using the appropriate positive and negative tissue field of views and are pathologist verified.
Recommended Usage: 1 uL per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application. Suggested starting range is 1:100.
- Wimberly, H. et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015; 3(4): 326-332.
- Bindels, S. et al. Regulation of PD-L1 by SIP1 in human epithelial breast tumor cells. Oncogene. 2006; 25:4975–4985.
* Conjugate tested on human tissue.